Proteomic Study of Autologous Serum Eye Drops in Adults With Severe Dry Eye Syndrome Single-Center Clinical Research

What this Trial Is About

Dry eye syndrome is a complex condition affecting the surface of the eye, with a prevalence of about 15% in adults aged 50 to 95. This trial focuses on severe forms of dry eye syndrome that do not respond to conventional treatments. Researchers aim to understand the differences in protein makeup of autologous serum eye drops and how these differences relate to patient responses. Participants will receive autologous serum eye drops, which contain proteins similar to those found in natural tears. The study will screen and measure the proteins in the serum eye drops to identify those linked to clinical improvement, focusing on responders versus non-responders. The treatment period lasts for 6 months, during which clinical and protein composition data will be collected and analyzed. Throughout the study, participants will be monitored for symptom improvement using scores like the Oxford score and OSDI. Medical data including causes of dry eye and treatment history will be gathered. The main outcome is to evaluate the relative abundance of proteins in the eye drops after 6 months. Safety and treatment response will be assessed over this period, with ongoing follow-up to track changes.

Study of Proteomic Factors in Patients With Severe Dry Eye Syndrome Treated With Autologous Serum Eye Drops.